immunitoAI, a biotech startup working on an AI-powered antibody discovery and screening platform, revealed on Wednesday that it has secured $1 million in a seed round led by Pi Ventures and including current investor Entrepreneur First. This is the first investment from pi Ventures’ Fund 2, which was announced in April 2021.
Aridni Shah and Trisha Chatterjee founded immunitoAI in November 2020 to generate and screen antibody candidates for a specific antigen. The business hopes to dramatically increase the number of antibodies discovered with this approach, making targeted therapy a standard in the future.
Aridni Shah, CEO and Co-founder, immunitoAI, said, “Integration of AI with biology has become a reality today. Biology has always been difficult to study and understand, but with the use of AI, we have started to bridge the gaps and what was thought to be impossible earlier has become possible. Our vision is to make antibody therapy a norm with the help of our technology. We plan on using this seed funding to develop our AI products and validate the predictions through biological experiments.”
Sharing her views on the investment, Roopan Aulakh, Managing Director, pi Ventures said, “Our focus at pi has been to invest in startups that are revolutionizing industries using disruptive technology. This thesis is well reflected in immunitoAI, our first investment from our recently launched Fund II. The company’s AI-led platform will make the antibody discovery process faster and cheaper, enabling targeted therapy for multiple diseases. We are delighted to partner with Aridni and Trisha, who bring a unique combination of biotech and AI to the table.”